Nanotheranostics in epilepsy: A perspective for multimodal diagnosis and strategic management

Abstract Epilepsy is a common but a complex neurological disorder with limited practices for successful management due to the complicated neuronal network and lack of knowledge of epileptic pathophysiology. Theranostic systems such as implantable devices and biodegradable nanomaterials offer better tailor‐made methods for the detection and treatment using nanotechnology‐based approaches for patients with epilepsy. Miniaturized nano‐implantable devices and biosensors equipped with operations to mimic neurostimulation demonstrate excellent opportunities in profiling the disease and assist in comprehension of the relationship between the disease and host. This strategy is developed for diagnoses and mapping brain activities to integrate and target therapeutic nanosystems in epilepsy. Non‐invasive class of nanotheranostics such as biodegradable and stimuli‐responsive polymers includes nanomaterials that utilize bio‐physico‐chemical processes or stimuli as a source for detecting the state and progress of the disease. The superior form of nanotheranostics encompasses in‐situ diagnostics with triggered release at the specific site. This review article focuses on the nanotheranostic strategies for epilepsy, their implications, challenges and new potentials for detection and therapy in personalized medicine. The concept of “on‐demand” release of drugs at the site of action using bio‐responsive theranostic approach reveals a potential for developing a point of primary care for epilepsy in the future.